AptarGroup, Inc. completed the acquisition of 64.6% stake in Voluntis S.A. from Vesalius Biocapital Partners S.à r.l, LBO France, Sham Innovation Santé, Bpifrance Participations SA, Debiopharm Innovation Fund SA and Eric Carreel.
AptarGroup, Inc. (NYSE:ATR) completed the acquisition of 64.6% stake in Voluntis S.A. from Vesalius Biocapital Partners S.à r.l, LBO France, Sham Innovation Santé, Bpifrance Participations SA, Debiopharm Innovation Fund SA and Eric Carreel in September 2, 2021. French Ministry of Economy has approved the transaction under the foreign investment clearance regulations. On September 2, 2021, following resignation of the selling shareholders' representatives on the Voluntis Board, namely Laurent Higueret (representative of Bpifrance Participations) and Franck Noiret (representative of LBO France Gestion), Gael Touya and Patrick Jeukenne, Aptar's representatives, have been appointed to replace them in the Board. The Board has also appointed M. Sai Shankar as deputy Chief Executive Officer of Voluntis, and the current management of Voluntis is otherwise expected to remain the same.